Posted by Michael Wonder on 09 Nov 2020
NICE issues positive Final Appraisal Determination for AbbVie’s Rinvoq (upadacitinib) in severe active rheumatoid arthritis
6 November 2020 - Positive recommendation means upadacitinib will be available to those with previously treated severe active rheumatoid arthritis.
The National Institute for Health and Care Excellence has issued a positive Final Appraisal Determination recommending upadacitinib, a once-daily oral therapy, for people with previously treated severe active rheumatoid arthritis.
The decision means that people with severe rheumatoid arthritis may now benefit from upadacitinib, which is the only treatment to have demonstrated improved rates of clinical remission versus the current standard of care in the treatment of the disease (adalimumab + methotrexate).
